AI-powered virtual assistant will be used to streamline entire pre- and post-vaccine distribution process for patients SAN FRANCISCO–(BUSINESS WIRE)–Following recent FDA approval of the first two COVID-19 vaccines, GYANT, the AI-powered virtual assistant company, today announced that its vaccine care navigation tool, GYANT Vaccine, has continued to gain traction since its launch in October. The solution is being deployed by numerous health systems, including Hackensack Meridian Health, MLK Community Healthcare, and Edward-Elmhurst Health, to facilitate the pre- and post-vaccine process in the weeks and months ahead. With the Pfizer vaccine FDA approved and already being distributed, and Moderna’s vaccine recently granted Emergency Use Authorization, health systems are looking to virtual assistants to build an infrastructure to efficiently manage each stage of rollout. GYANT Vaccine virtually guides patients through the entire pre- and post-vaccination process, from screening to scheduling and proactive follow-ups, to alert patients about eligibility and monitor potential side effects. The solution helps health systems pre-qualify individuals and facilitate deployment in direct alignment with phased or prioritized availability. Moreover, it adapts to each provider’s changing requirements over the course of the vaccine rollout.